Trial Site Detail

 

Drug:
IDRX-42
Trial:
A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy (StrateGIST 3)
Conditions: Gastrointestinal Stromal Tumor
Trial Status:
Recruiting

 

Gabrail Cancer Center

4875 Higbee Ave, NW     
Canton , OH 44718
USA

 

Principal Investigator:
 Nashat Gabrail
Contact:
 330-492-3345 Appointments: Shelly Rentsch srentsch@gabrailcancercenter.com 330-492-3345
Activation Status of this Site:
 Active
Notes about this Site:
Gabrail Cancer Center Website:

 

 

Navigating the Map

Use the plus (+) and minus (-) controls to zoom in/out.

Click and drag the map or use the arrows to move (pan) the map.

Tip: Click the marker before zooming and the map will stay centered on the marker as you zoom.